In roughly the same time frame, people taking oral semaglutide (Rybelsus) lost about 4.2% of their body weight (7.5 pounds)
Summary Heart palpitations are relatively uncommon among semaglutide users, with one source reporting about 1% and broader summaries noting cardiovascular side effects under 5%, so most patients will not develop persistent arrhythmias
The results for the primary endpoint at 26 weeks are summarized in Table 6
Skin irritation at the application site is the most reported adverse effect
If you are pregnant, breastfeeding, taking any medication or under medical supervision, please consult a doctor before use
For those looking for evidence-based ways to support their health, peptide therapy offers a way to work with the bodys own regulatory systems, rather than overriding them